Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial
Authors
Andrew, R. P.Richard, J.
Silvia, C.
Fotis, P.
Christina, Y.
James, D.
Matthew, B.
Michael, S.
Umair, T. K.
Stacey, C.
Melanie, O.
Ke, L.
Sarah, E. C.
Geetha, M.
Nagesh, K.
Helen, M.
Bloor, Adrian
Anna, S.
Andrew, D.
Claire, D.
Christopher, F.
Ben, K.
Renata, W.
Scott, M.
Christopher, P. F.
Peter, H.
Affiliation
University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.Issue Date
2020
Metadata
Show full item recordAbstract
NoneCitation
Andrew RP, Richard J, Silvia C, Fotis P, Christina Y, James D, et al. Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. Haematologica. 2020;105(12):2868-71.Journal
HaematologicaDOI
10.3324/haematol.2019.230805PubMed ID
33256390Additional Links
https://dx.doi.org/10.3324/haematol.2019.230805Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3324/haematol.2019.230805
Scopus Count
Collections
Related articles
- A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
- Authors: Lee CH, Chen PH, Lin C, Wang CY, Ho CL
- Issue date: 2020
- Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
- Authors: Hoyle M, Crathorne L, Garside R, Hyde C
- Issue date: 2011 May
- Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
- Authors: Grey M
- Issue date: 2008 Jul
- Ofatumumab.
- Authors: Sanford M, McCormack PL
- Issue date: 2010 May 28
- Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
- Authors: Lee D
- Issue date: 2004 Mar